Clinical efficacy, safety and pharmacokinetic properties of the plasma-derived factor IX concentrate Haemonine ® in previously treated patients with severe haemophilia B

Haemophilia

Volumn 18, Issue 2, 2012, Pages 175-181

  Serban, M ^a   Skotnicki, A B ^b   Colovic, M ^c   Jinca, C ^a   Klukowska, A ^d   Laguna, P ^d   Wolf, D M ^e  

^a Louis Turcanu'   (Romania)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^c Institute of Haematology   (Serbia)

^d MEDICAL UNIVERSITY OF WARSAW   (Poland)

^e BIOTEST AG   (Germany)

Author keywords

Factor IX; Haemophilia B; Half life; Incremental recovery; Pharmacokinetics; Safety

Indexed keywords

BLOOD CLOTTING FACTOR 9 CONCENTRATE; HAEMONINE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; BLEEDING; CHILD; CLINICAL ARTICLE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; FEMALE; HEMOPHILIA B; HEMOSTASIS; HUMAN; MALE; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ADULT; BLOOD COAGULATION FACTORS; CHILD; FACTOR IX; HALF-LIFE; HEMOPHILIA B; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84857110515     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2011.02624.x     Document Type: Article

References (15)

1. White GC, Beebe A, Nielsen B. Recombinant factor IX. Thromb Haemost 1997; 78: 261-5.
2. Roth DA, Kessler CM, Pasi KJ, Rup B, Courter SG, Tubridy KL. Recombinant Factor IX Study Group. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood 2001; 98: 3600-6.
3. Horowitz B, Wiebe ME, Lippin A, Stryker MH. Inactivation of viruses in labile blood derivates. I. Disruption of lipid-enveloped viruses by tri (n-butyl) phosphate detergent combinations. Transfusion 1985; 25: 516-22.
4. The European Agency for the Evaluation of Medicinal Products (EMEA). Note for guidance on the clinical investigation of human plasma derived factor VIII and IX products. CPMP/BPWG/198/95 rev. 1, October 19, 2000, coming into operation April 2001.
5. The European Agency for the Evaluation of Medicinal Products (EMEA). Core SPC for human plasma derived and recombinant coagulation factor IX products. CPMP/BPWG/1625/99, June 29, 2000, coming into operation December 2000.
6. Kasper CK, Aledort LM, Counts RB et al. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 869-72.
7. Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factorVIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247-51.
8. Björkman S, Carlsson M. The pharmacokinetics of factor VIII and factor IX: methodology, pitfalls and applications. Haemophilia 1997; 3: 1-8.
9. Carlsson M, Björkman S. Multidose pharmacokinetics of factorIX: implications for dosing in prophylaxis. Haemophilia 1998; 4: 83-8.
10. Goudemand J, Peynet J, Chambost H et al. A cross-over pharmacokinetic study of a double viral inactivated factor IX concentrate (15nm filtration and SD) compared with a SD factor IX concentrate. Thromb Haemost 1998; 80: 919-24.
11. Seliger I, Anstadt M, Brückmann C. Consistency of recovery and half-life of Immunate and Immunine in first-time recipients over a period of 3-6 months. Presented at the XXIV International Congress of the World Federation of Hemophilia, July 16-21, Montreal, Canada, 2000.
12. Björkman S, Berntorp E. Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. Clin Pharmacokinet 2001; 40: 815-32.
13. Berntorp E, Björkman S. The pharmacokinetics of clotting factor therapy. Haemophilia 2003; 9: 353-59.
14. Ewenstein BM, Joist JH, Shapiro AD et al. Pharmacokinetic analysis of plasma-derived and recombinant FIX concentrates in previously treated patients with moderate or severe hemophilia B. Transfusion, 2002; 42: 190-7.
15. Morfini M. Pharmacokinetics of factor VIII and factor IX. Haemophilia 2003; 9(Suppl 1): 94-9.